Paul Hastings LLP advised Xencor, Inc. on the offering. Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Xoma Corporation on the deal. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator announced its multi-license and milestone monetization transaction with Viracta Therapeutics....
You must be a Standard 1 Year member to access this content.
